NDA 219683 · Janssen Biotech
Inlexzo
Gemcitabine Hydrochloride · Intravesical · Nucleoside Metabolic Inhibitor
Breakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Sep 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 9, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3,514
702 Phase 3, 512 recruiting
FAERS reports
484
108 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
INLEXZO is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. INLEXZO is a nucleoside metabolic inhibitor-containing intravesical system, indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )
Mechanism: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabine triphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 9, 2025 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyLabelLetterReview
1 products under this application
- INLEXZO · GEMCITABINE HYDROCHLORIDE EQ 225MG BASE · SYSTEM, INTRAVESICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Gemcitabine" as an intervention, any sponsor and status, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00093795 · 4,894 participants · Start Oct 2004 · Primary completion Mar 2012
Drug: Cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Stuart, Florida · 12 sites in all
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00011986 · 4,312 participants · Start Jan 2001 · Primary completion Mar 2010
Drug: Paclitaxel; Carboplatin and 3 more · For: Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Sites: Philadelphia, Pennsylvania
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-TrialPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02181101 · 3,754 participants · Start Sep 2005 · Primary completion Sep 2013
Drug: FEC-DocGemzar adjuvant chemotherapy; FEC-Doc adjuvant chemotherapy and 2 more · For: Breast Neoplasms
Sites: Munich, Germany
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
University of ZurichAcademic, hospital or other
NCT00490360 · 2,007 participants · Start Oct 2001
Drug: Gemcitabine / Cisplatin · For: Cancer of the Pancreatic Head
Sites: Zurich, Switzerland
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerPivotal-lookingCompleted
AGO Study GroupAcademic, hospital or other
NCT00052468 · 1,742 participants · Start Aug 2002 · Primary completion Jul 2009
Drug: TCG; TC · For: Fallopian Tube Cancer; Ovarian Cancer
Sites: Copenhagen, Denmark; Paris, France; Bremen, Germany · 17 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pollakiuria96
- dysuria94
- micturition urgency52
- urinary tract infection45
- bladder pain38
- bladder spasm31
- haematuria27
- drug intolerance25
- pain22
- product dose omission issue19
- lower urinary tract symptoms18
- adverse event15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 26 |
| 2026 | 458 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T, Desseigne F, Ychou M, et al. · N Engl J Med 2011 · Clinical Trial, Phase II, Clinical Trial, Phase III
- NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
Wainberg ZA, Melisi D, Macarulla T, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Oh DY, He AR, Bouattour M, et al. · Lancet Gastroenterol Hepatol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD, Ervin T, Arena FP, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E, van Dam JL, Suker M, et al. · J Clin Oncol 2022 · Multicenter Study, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.